Efficacy of efpeglenatide in patients with obesity and prediabetes: a subanalysis of the BALANCE 205 study

Publication Authors:

Ogbaa I, Pratley R, Jacob S, Kang J, Trautmann M, Hompesch M, Han O, Stewart J, Sorli C, Yoon K

Poster presented at 55th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, Spain. 2019 Sept.

About this poster:

Once-weekly (QW), subcutaneous efpeglenatide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) being developed to improve glycaemic control in type 2 diabetes mellitus.

In the 20-week BALANCE 205 study, all doses of efpeglenatide led to significant reductions in body weight (BW) vs placebo (PBO) in patients with obesity without diabetes (p<0.0001; primary endpoint). This exploratory analysis investigated the effects of efpeglenatide on glycaemic control, BW, BMI, waist circumference (WC) and cholesterol parameters in patients from BALANCE with prediabetes (HbA1c39−46 mmol/mol; 5.7%−6.4% or fasting plasma glucose [FPG] 5.6−6.9 mmol/L; 100−125 mg/dL) at baseline (n=140/295).